News Change at the top of Recursion as co-founder leaves CEO role After 12 years as CEO of 'techbio' player Recursion, Chris Gibson is switching to the role of chair and will be replaced by Najat Khan.
News Merck's rare tumour drug Pimjetmi claims FDA approval Merck's Pimjetmi has been cleared in the US for tenosynovial giant cell tumour, adding a third FDA-approved treatment for the rare disorder.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.